ReportWire

Tag: sexually transmitted diseases

  • Australia approves world-first vaccine to save koalas from chlamydia

    MELBOURNE, Australia — A regulator has approved a world-first vaccine to protect koalas from chlamydia infections, which are causing infertility and death in the iconic native species that is listed as endangered in parts of Australia.

    The single-dose vaccine was developed by the University of the Sunshine Coast in Queensland state after more than a decade of research led by professor of microbiology Peter Timms.

    The research showed the vaccine reduced the likelihood of koalas developing symptoms of chlamydia during breeding age and decreased mortality from the disease in wild populations by at least 65%.

    The recent approval by Australia’s veterinary medicine regulator means the vaccine can now be used in wildlife hospitals, veterinary clinics and in the field to protect the nation’s most at-risk koalas, Timms said on Wednesday.

    “We knew a single-dose vaccine — with no need for a booster — was the answer to reducing the rapid, devastating spread of this disease, which accounts for as much as half of koala deaths across all wild populations in Australia,” Timms said in a statement.

    “Some individual colonies are edging closer to local extinction every day, particularly in southeast Queensland and New South Wales, where infection rates within populations are often around 50% and in some cases can reach as high as 70%,” Timms added.

    Deborah Tabart, chair of the conservation charity Australian Koala Foundation, said resources being spent on vaccinating koalas should be redirected at saving koala habitat.

    “At the risk of sounding flippant, how can anyone be so delusional as to think that you can vaccinate 100,000 animals? It’s just ridiculous,” Tabart said on Friday.

    Tabart’s foundation estimates there are fewer than 100,000 koalas in the wild. The government-backed National Koala Monitoring Program estimated last year there were between 224,000 and 524,000 koalas.

    “I accept that chlamydia is an issue for koalas, but I also want people to understand that they’re sick because they haven’t got any habitat,” Tabart said.

    The Queensland Conservation Council, an umbrella organization for more than 50 environmental groups across the state, welcomed the vaccine. But the council’s director, Dave Copeman, echoed Tabart’s focus on preserving koala habitat.

    “It’s really good news. Chlamydia is one of the key stresses that has been putting pressure on koala populations,” Copeman said.

    “Koalas were at risk before chlamydia outbreaks, and they will remain at risk even if we manage chlamydia perfectly, because we keep on destroying their habitat,” he added.

    Koalas are listed as endangered species in the states of Queensland and New South Wales and in the Australian Capital Territory, with habitat loss due to wildfires and urban expansion as the major threats. Chlamydia can cause urinary tract infections, infertility, blindness and death.

    Treatment with antibiotics can disrupt an infected koala’s ability to digest eucalyptus leaves — its sole food source — leading to starvation, the university said in a statement.

    The research has been supported by the federal, New South Wales and Queensland governments.

    Federal Environment Minister Murray Watt said his government had contributed to the vaccine’s development through a 76 million Australian dollar ($50 million) Saving Koalas Fund.

    “We know that koalas need help to fight diseases like chlamydia. It’s a widespread threat impacting their reproductive health and causing infertility,” Watt said in a statement.

    Koalas are iconic Australian marsupials, like wombats and kangaroos. They spend most of their time eating and sleeping in eucalyptus trees, and their paws have two opposing thumbs to help them grasp and climb up tree trunks.

    Australia’s wild koala populations have declined steeply in the past two decades.

    Facing compounded threats from disease, habitat loss, climate change and road collisions, koalas could become extinct by 2050, according to a 2020 assessment from the New South Wales government.

    Source link

  • Moderna is developing a Lyme disease vaccine in a first for the company

    Moderna is developing a Lyme disease vaccine in a first for the company

    Moderna Inc. said Tuesday it’s working to develop its first bacterial vaccine to protect against Lyme disease, the tick-borne illness that causes a range of painful symptoms, including fever, headaches, fatigue, joint pain and rash.

    The biotech
    MRNA,
    -2.75%
    ,
    whose first product to be approved by the U.S. Food and Drug Administration was its mRNA-based COVID vaccine, said it has two candidates in development to address Lyme disease, named mRNA-1982 and mRNA-1975.

    It announced the news at its fourth Vaccine Day, where it offered a full update on its clinical pipeline, which includes vaccines to protect against flu and respiratory syncytial virus, or RSV, as well as HIV, Epstein-Barr virus and herpes simplex virus, among others.

    There are about 120,000 cases of Lyme disease in the U.S. and Europe every year, creating a “significant quality of life burden,” the company said in a statement. Rising temperatures are helping the disease spread more easily, and it is difficult to diagnose, because the symptoms are similar to those of many other diseases. It most seriously affects children below the age of 15 and older adults.

    “Older adults appear to have higher odds of unfavorable treatment response as compared with younger patients, and neurologic manifestations are more common at presentation for this older adult population,” said the statement.

    Tick and Lyme disease season is here, and scientists warn this year could be worse than ever. Dr. Goudarz Molaei joins Lunch Break’s Tanya Rivero to explain what triggered the rapid spread of the disease and how people can avoid being affected. Photo: Kent Wood/Science Source

    The mRNA-1982 candidate is designed to create antibodies for Borrelia burgdorferi, the pathogen that causes almost all Lyme disease in the U.S., while mRNA-1975 is designed to elicit antibodies specific to the four major Borrelia species that cause the disease in the U.S. and Europe.

    Other new candidates in Moderna’s pipeline include mRNA-1405 and mRNA-1403, which aim to address the enteric virus norovirus. Norovirus is highly contagious and is the leading cause of diarrheal disease globally, Moderna said. It’s associated with about 18% of all such illnesses worldwide and causes about 200,000 deaths every year.

    Overall, Moderna is expecting to launch six major vaccine products in the next few years, all of them with large addressable markets.

    The company expects the annual global endemic market for COVID boosters alone to be worth about $15 billion.

    It has dosed the first participant in a late-stage trial of its next-generation, refrigerator-stable COVID-19 vaccine candidate, mRNA-1283. The vaccine “has demonstrated encouraging results in multiple clinical studies,” the company said.

    See now: Moderna CEO defends price increase for COVID vaccine to Congress

    A separate trial of a flu vaccine called mRNA-1010 fared less well, however.

    That trial “did not accrue sufficient cases at the interim efficacy analysis to declare early success in the Phase 3 Northern Hemisphere efficacy trial and the independent DSMB recommended continuation of efficacy follow-up,” the company said.

    The company expects the market for respiratory-product sales to range from $8 billion to $15 billion by 2027 and for operating profit that year to range from $4 billion to $9 billion.

    The stock was down 4% Tuesday and has fallen 15% in the year to date, while the S&P 500
    SPX,
    +0.17%

    has gained 7%.

    See also: Moderna’s stock slides as earnings fall short of estimates amid steep decline in COVID-vaccine sales

    Source link

  • Opinion: Women don’t have to die from cervical cancer | CNN

    Opinion: Women don’t have to die from cervical cancer | CNN

    Editor’s Note: Dr. Eloise Chapman-Davis is director of gynecologic oncology at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine. Dr. Denise Howard is chief of obstetrics and gynecology at NewYork-Presbyterian Brooklyn Methodist Hospital and a vice chair of obstetrics and gynecology at Weill Cornell Medicine. The views expressed in this commentary are their own. Read more opinion on CNN.



    CNN
     — 

    As doctors who specialize in women’s reproductive health, we are on the front lines of a preventable crisis. Imagine treating a woman with advanced cancer who has a five-year survival rate of 17%, knowing that she should have never developed the deadly disease in the first place.

    This is what we are facing with cervical cancer. Yet we have the clinical tools not only to lower but also eliminate nearly all the roughly 14,000 new cases and 4,300 deaths from cervical cancer each year.

    Denise Howard

    We have effective screenings: the traditional Pap smear and the HPV test. If these screening tests are abnormal, additional tests can determine who needs further treatment to prevent the development of cancer. Importantly, we have the HPV vaccine, which protects against high-risk human papillomavirus (HPV) types that cause the majority of cervical cancer cases and is nearly 100% effective, according to the National Cancer Institute.

    A report published earlier this month shows the vaccine’s tremendous impact. The US saw a 65% drop in cervical cancer rates from 2012 through 2019 among women ages 20-24, the first to have received the vaccine. The vaccine, combined with screening, could wipe out cervical cancer and make it a disease of the past.

    But the percentage of women overdue for their cervical cancer screening is growing, and, alarmingly, late-stage cases are on the rise.

    We have had the heartbreaking experience of seeing mothers in the prime of life die from this avoidable disease, leaving small children behind — even women who had an abnormal screening but never received follow-up care. It’s devastating to see an otherwise healthy person slowly die from a preventable cancer.

    Simply put, cervical cancer should never occur. This Cervical Cancer Awareness Month, we should commit to making that a reality. Here is what needs to happen.

    Eliminating cervical cancer requires commitment at multiple levels, from public awareness campaigns with culturally appropriate messaging that broadcasts the power of the vaccine and screenings to prevent cancer to resources that ensure all women have easy access to routine health exams.

    Timely screening reminders and systems to prioritize follow-up care are essential. Too many women with abnormal screenings don’t receive their results, reminders or follow-up instructions they understand and, therefore don’t receive the proper treatment. Barriers also include logistical challenges like transportation and language issues. Studies suggest that 13% to 40% of cervical cancer diagnoses result from lack of follow-up among women with an abnormal screening test.

    Gynecology and primary care practices should be vigilant about reaching and monitoring patients with suspicious test findings. Large health systems can leverage the power of the electronic health record to track abnormal tests and ensure these women receive the proper follow-up.

    Pediatricians should encourage parents of children 9 and older to get the HPV vaccine and stress its safety. About 60% of teenagers are up to date on their HPV vaccines, according to the US Centers for Disease Control and Prevention. Physicians not recommending the vaccine and parents’ rising concerns about its safety, despite more than 15 years of evidence that it is safe and effective, have been cited as top reasons why more children aren’t receiving this lifesaving vaccine.

    College campuses should do large-scale, catch-up vaccination outreach. These students are at high risk for contracting HPV, yet only half report having received the full HPV vaccine series. This service should be provided at no cost to students.

    Stark racial disparities also must be addressed. As Black women physicians, we are frustrated that Black women continue to be more likely to die from the disease than any other race, according to the American Cancer Society. The system failures contributing to this tragedy range from Black women receiving less aggressive treatment to barriers around access to affordable routine health care and the high-quality, specialized treatment needed to treat cancer. Everyone deserves access to quality care.

    Older patients should be told that approval of the HPV vaccine has been extended up to age 45 and to discuss with their doctor whether it’s right for them. Insurance providers should cover the cost of the vaccine for these older ages.

    Women should see a gynecologist on a regular basis well into their older years. We see patients with cervical cancer in their 60s and 70s who haven’t been screened in 20 years. Many people stop seeing a gynecologist after childbearing or menopause, but this shouldn’t be the case. Getting quality gynecological exams throughout a woman’s life is critical to preserving it.

    We also need to empower women to be their own advocates through health education. Women should receive their screening result with an explanation of what it means and any next steps clearly delineated. No news after a screening is not good news. In an ideal world, women would see their HPV status as essential information with the power to save their lives.

    Education makes a difference. At NewYork-Presbyterian and Weill Cornell Medicine, we produced a series of easy-to-understand, publicly available videos on cervical cancer and the HPV vaccine. We showed several of the vaccine videos to more than 100 parents in one of our pediatric practices that serves mostly low-income families as part of a pilot study. Their knowledge scores on a questionnaire about the vaccine and HPV that they completed before and after watching the videos increased nearly 80%, and roughly 40% of the unvaccinated children received the HPV vaccine within one month. We aim to expand this effort.

    We have the tools to prevent cervical cancer but fail to use them effectively. It’s unacceptable, and we can no longer ignore the problem. It’s time for a full-scale offensive focused on all fronts to make cervical cancer a disease of the past.

    Source link